Aktemra - pervyy i edinstvennyy biologicheskiy preparat, demonstriruyushchiy prevoskhodstvo nad sushchestvuyushchimi standartami terapii revmatoidnogo artrita

Abstract

Novyy preparat dlya lecheniya revmatoidnogo artrita (RA) - Aktemra (totsilizumab) - prodemonstriroval prevoskhodstvo nad sushchestvuyushchim standartom terapii (metotreksat): posle 6 mes priema preparata nablyudaetsya bolee znachitel'noe snizhenie vyrazhennosti simptomov zabolevaniya (pripukhlost' i boleznennost' sustavov) u patsientov, stradayushchikh RA1. Bolee togo, pri ispol'zovanii Aktemry primerno v 3raza bol'she patsientov (po sravneniyu s metotreksatom) dostigli remissii (po kriteriyam DAS 28 <2,6)2 - osnovnoy tseli terapii etogo poka neizlechimogo zabolevaniya1. Etot rezul'tat chrezvychayno vazhen, poskol'ku RA yavlyaetsya dlitel'nym invalidiziru-yushchim zabolevaniem i sushchestvuyushchie lekarstvennye sredstva dayut lish' nebol'shuyu nadezhdu na dostizhenie remissii; po sushchestvu,
ostro neobkhodimy novye varianty terapii RA. Uil'yam M. Berns - glava podrazdeleniya Farma kompanii «Rosh»: «Dannye poslednikh issledovaniy yavlyayutsya obnadezhivayushchey novost'yu dlya patsientov, stradayushchikh ot razrushitel'nykh effektov RA. My verim, chto Aktemra - pervyy i edinstvennyy biologicheskiy preparat, demonstriruyushchiy preimushchestvo pered sushchestvuyushchimi standartami lecheniya RA, - oblegchit sostoyanie mnogikh bol'nykh. Krome togo, Aktemra predostavlyaet bol'she shansov dlya dostizheniya ranney i prodolzhitel'noy remissii».